1. Home
  2. WVE vs FIHL Comparison

WVE vs FIHL Comparison

Compare WVE & FIHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • FIHL
  • Stock Information
  • Founded
  • WVE 2012
  • FIHL 2014
  • Country
  • WVE Singapore
  • FIHL Bermuda
  • Employees
  • WVE N/A
  • FIHL N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • FIHL
  • Sector
  • WVE Health Care
  • FIHL
  • Exchange
  • WVE Nasdaq
  • FIHL Nasdaq
  • Market Cap
  • WVE 2.1B
  • FIHL 2.0B
  • IPO Year
  • WVE 2015
  • FIHL 2023
  • Fundamental
  • Price
  • WVE $10.99
  • FIHL $16.60
  • Analyst Decision
  • WVE Strong Buy
  • FIHL Buy
  • Analyst Count
  • WVE 10
  • FIHL 8
  • Target Price
  • WVE $21.60
  • FIHL $20.88
  • AVG Volume (30 Days)
  • WVE 1.0M
  • FIHL 588.9K
  • Earning Date
  • WVE 03-05-2025
  • FIHL 02-27-2025
  • Dividend Yield
  • WVE N/A
  • FIHL 1.80%
  • EPS Growth
  • WVE N/A
  • FIHL N/A
  • EPS
  • WVE N/A
  • FIHL 3.96
  • Revenue
  • WVE $53,610,000.00
  • FIHL $2,299,900,000.00
  • Revenue This Year
  • WVE N/A
  • FIHL N/A
  • Revenue Next Year
  • WVE $48.58
  • FIHL $14.00
  • P/E Ratio
  • WVE N/A
  • FIHL $4.20
  • Revenue Growth
  • WVE N/A
  • FIHL N/A
  • 52 Week Low
  • WVE $3.50
  • FIHL $12.20
  • 52 Week High
  • WVE $16.74
  • FIHL $21.32
  • Technical
  • Relative Strength Index (RSI)
  • WVE 34.06
  • FIHL 36.07
  • Support Level
  • WVE $10.57
  • FIHL $15.92
  • Resistance Level
  • WVE $12.03
  • FIHL $16.78
  • Average True Range (ATR)
  • WVE 0.69
  • FIHL 0.40
  • MACD
  • WVE -0.17
  • FIHL -0.02
  • Stochastic Oscillator
  • WVE 12.54
  • FIHL 36.33

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.

Share on Social Networks: